Zura Bio Limited Class A Ordinary Shares ZURA
i
Market datapartial · fetched 2026-11-06T22:46:39.465Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T22:45:28.140647077Z
FundamentalsAlpha Vantage · unavailable
Zura Bio Limited Class A Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.94 | 406.4% | 44.2% | |||
| 25Δ | 9.98 | 415.2% | 149.0% | 3.37 | 412.2% | 39.7% |
| 30Δ | 9.36 | 436.5% | 136.7% | 3.80 | 418.0% | 35.2% |
| 35Δ | 8.67 | 452.8% | 122.7% | 4.29 | 426.5% | 31.4% |
| 40Δ | 7.88 | 462.3% | 106.6% | 4.84 | 437.3% | 28.1% |
| 45Δ | 7.06 | 463.0% | 89.5% | 5.42 | 440.7% | 24.8% |
| 50Δ | 6.20 | 455.2% | 71.6% | 6.02 | 440.4% | 21.6% |
| 55Δ | 5.12 | 398.4% | 46.9% | 6.48 | 422.4% | 18.4% |
| 60Δ | 4.53 | 364.2% | 34.3% | 6.93 | 404.3% | 15.3% |
| 65Δ | 4.00 | 334.5% | 23.5% | 7.39 | 386.3% | 12.2% |
| 70Δ | 3.67 | 326.9% | 19.4% | 8.61 | 403.1% | 10.1% |
| 75Δ | 3.34 | 319.3% | 15.3% | |||
| 80Δ | 3.01 | 311.7% | 11.2% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.94
- IV
- 406.4%
- B/E move
- 44.2%
25Δ
- Pseudo strike
- 9.98
- IV
- 415.2%
- B/E move
- 149.0%
- Pseudo strike
- 3.37
- IV
- 412.2%
- B/E move
- 39.7%
30Δ
- Pseudo strike
- 9.36
- IV
- 436.5%
- B/E move
- 136.7%
- Pseudo strike
- 3.80
- IV
- 418.0%
- B/E move
- 35.2%
35Δ
- Pseudo strike
- 8.67
- IV
- 452.8%
- B/E move
- 122.7%
- Pseudo strike
- 4.29
- IV
- 426.5%
- B/E move
- 31.4%
40Δ
- Pseudo strike
- 7.88
- IV
- 462.3%
- B/E move
- 106.6%
- Pseudo strike
- 4.84
- IV
- 437.3%
- B/E move
- 28.1%
45Δ
- Pseudo strike
- 7.06
- IV
- 463.0%
- B/E move
- 89.5%
- Pseudo strike
- 5.42
- IV
- 440.7%
- B/E move
- 24.8%
50Δ
- Pseudo strike
- 6.20
- IV
- 455.2%
- B/E move
- 71.6%
- Pseudo strike
- 6.02
- IV
- 440.4%
- B/E move
- 21.6%
55Δ
- Pseudo strike
- 5.12
- IV
- 398.4%
- B/E move
- 46.9%
- Pseudo strike
- 6.48
- IV
- 422.4%
- B/E move
- 18.4%
60Δ
- Pseudo strike
- 4.53
- IV
- 364.2%
- B/E move
- 34.3%
- Pseudo strike
- 6.93
- IV
- 404.3%
- B/E move
- 15.3%
65Δ
- Pseudo strike
- 4.00
- IV
- 334.5%
- B/E move
- 23.5%
- Pseudo strike
- 7.39
- IV
- 386.3%
- B/E move
- 12.2%
70Δ
- Pseudo strike
- 3.67
- IV
- 326.9%
- B/E move
- 19.4%
- Pseudo strike
- 8.61
- IV
- 403.1%
- B/E move
- 10.1%
75Δ
- Pseudo strike
- 3.34
- IV
- 319.3%
- B/E move
- 15.3%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 3.01
- IV
- 311.7%
- B/E move
- 11.2%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 236.13% | |
| 257.90% |
Biotechnology
ZVRA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The…
More →ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in…
More →AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the…
More →ABCL
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
More →ABEO
Description unavailable
More →ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative…
More →